Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has presented data at the Virtual ISPOR Europe 2020 Conference on two severe childhood genetic disorders: Aromatic L-Amino acid Decarboxylase deficiency (AADC-d) and Duchenne muscular dystrophy caused by nonsense mutations (nmDMD). The findings highlight the significant health burdens of these conditions and the urgent need for effective therapies. PTC's gene therapy, PTC-AADC, is under review by the EMA, with a decision expected in the first half of 2021. Additionally, a qualitative study on nmDMD underscores the critical need for therapies that alleviate the comprehensive impacts on patients and caregivers.
PTC Therapeutics (NASDAQ: PTCT) reported a 66% increase in total revenue to $118.4 million for Q3 2020, driven by the launch of Evrysdi for spinal muscular atrophy. The company achieved significant milestones, including $35 million in collaboration revenue from Roche. However, net loss widened to $69.7 million, compared to $60 million last year, with R&D expenses rising to $93 million. Cash and equivalents increased to $1.14 billion. PTC aims to enhance long-term value through innovative therapies.
On October 28, 2020, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of non-statutory stock options and restricted stock units (RSUs) for 18 new employees. A total of 18,610 stock options and 6,860 RSUs were granted as part of the employees' compensation. The stock options have an exercise price of $51.96 per share and a vesting schedule over four years. The inducement grants align with NASDAQ Listing Rule 5635(c)(4), established to attract new talent within the company.
PTC Therapeutics, trading under NASDAQ: PTCT, will present an overview at two upcoming virtual conferences. The Credit Suisse 29th Annual Virtual Healthcare Conference is scheduled for November 11, 2020, at 9:30 a.m. ET, and the Barclays Virtual Gene Editing & Gene Therapy Summit will occur on November 16, 2020, at 3:30 p.m. ET. These presentations will be streamed live and archived for two weeks on PTC's investor relations webpage. PTC focuses on developing innovative therapies for patients with rare disorders.
PTC Therapeutics (NASDAQ: PTCT) announced the launch of a Phase 2/3 clinical trial for vatiquinone (PTC743) aimed at treating mitochondrial epilepsy, a severe condition affecting children with inherited mitochondrial diseases. With approximately 11,000-13,000 potential patients across the US, EU, Japan, and Latin America, the trial is critical as it addresses a significant unmet medical need. Vatiquinone has shown promise in earlier studies, impacting seizure frequency and related morbidity in over 500 patients. The trial's primary endpoint focuses on reducing seizure frequency in a controlled setting.
PTC Therapeutics, along with the AADC Family Network, has announced October 23 as the first AADC Deficiency Awareness Day in Massachusetts. This designation aims to raise awareness about Aromatic L-amino Acid Decarboxylase (AADC) deficiency, a rare genetic disorder that significantly impacts affected children. To commemorate the day, PTC will host a Facebook Live event featuring industry experts, including Kelly Heger and Matthew Klein. The initiative highlights the ongoing efforts towards finding treatment options for this condition, which currently has no approved therapies.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that its drug, Evrysdi™ (risdiplam), received approval from Brazil's ANVISA for spinal muscular atrophy (SMA), marking its second country approval. Additionally, PTC filed a New Drug Application in Japan, which triggers a $7.5 million milestone payment from Roche. Evrysdi™ has been submitted for approval in 15 other markets and is undergoing reviews in four health authorities. The drug offers a new treatment option for SMA, which affects 1 in 10,000 babies. Its oral formulation is significant for patient accessibility during the COVID-19 pandemic.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on October 29, 2020, at 4:30 p.m. (ET), to report third quarter 2020 financial results and update its business outlook. Investors can access the call by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) with the passcode 7096445. A live webcast will also be available on the company’s website and a replay will be archived for 30 days. PTC focuses on developing medicines for rare disorders and aims to provide access to innovative treatments.
On September 28, 2020, PTC Therapeutics announced positive two-year data from the FIREFISH study on Evrysdi™ (risdiplam) for treating spinal muscular atrophy (SMA). The study indicated that 88% of infants were alive without permanent ventilation after two years. Significant motor milestones were achieved, including increased independent sitting and head control. The treatment's safety profile remained consistent, with no new safety signals. Evrysdi™ was recently approved and shows a strong commercial launch, highlighting its importance amid the ongoing pandemic.
PTC Therapeutics announced on September 21, 2020, the approval of stock options for 75,670 shares and 12,845 restricted stock units (RSUs) to 22 new employees, as part of their employment compensation. These inducement grants comply with NASDAQ's listing rules and aim to attract new talent. The options have an exercise price of $45.46 per share, with a 10-year term and a four-year vesting schedule. The RSUs will also vest over four years. PTC focuses on developing innovative treatments for rare disorders, driving their investment in a strong pipeline of medicines.